This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Conjugated and aggregated dendritic cell (DC) vaccine	<p>Studies in mice suggest that conjugation of a dual toll-like receptor 7 (TLR7) and TLR8 agonist to aggregated protein antigens could increase vaccine efficacy. Mice vaccinated with an aggregated form of <i>Listeria monocytogenes</i> protein linked to the dual TLR7 and TLR8 agonist resiquimod had better T cell activation and resistance to <i>L. monocytogenes</i> infection than controls given a nonaggregated protein linked to resiquimod. Next steps include formulating and testing conjugated, aggregated vaccines for malaria and tuberculosis antigens in animal models.</p> <p>Celldex Therapeutics Inc. has rights from 3M Co. to use resiquimod as an adjuvant in DC vaccines.</p> <p>SciBX 4(16); doi:10.1038/scibx.2011.468 Published online April 21, 2011</p>	Unpatented; licensing status not applicable	<p>Kastenmüller, K. <i>et al. J. Clin. Invest.</i>; published online April 11, 2011; doi:10.1172/JCI45416</p> <p>Contact: Robert A. Seder, National Institutes of Health, Bethesda, Md. e-mail: rseder@mail.nih.gov</p>